{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:56:17Z","timestamp":1790376977704,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Blanca Morell Foundation"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00164 APG"],"award-info":[{"award-number":["PI18\/00164 APG"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20-01132 FP"],"award-info":[{"award-number":["PI20-01132 FP"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01896 MMA"],"award-info":[{"award-number":["PI19\/01896 MMA"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008062","name":"Fundaci\u00f3n Alicia Koplowitz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","award":["PRYGN21937"],"award-info":[{"award-number":["PRYGN21937"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["817884"],"award-info":[{"award-number":["817884"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chadtough Defeat DIPG Foundation"},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.xcrm.2025.102204","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:16:27Z","timestamp":1750940187000},"page":"102204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2173-9416","authenticated-orcid":false,"given":"Sara","family":"Labiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Marco-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Ausejo-Mauleon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Laspidea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Hern\u00e1ndez-Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Garcia-Moure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel de la","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Gonzalez-Huarriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Phoenix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibon","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zalacain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lacalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Marrodan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Puigdelloses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irati","family":"Herv\u00e1s-Corpi\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren J.","family":"Becher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candelaria","family":"Gomez-Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fueyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"G\u00e1llego P\u00e9rez-Larraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pati\u00f1o-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-7351","authenticated-orcid":false,"given":"Marta M.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102204_bib1","doi-asserted-by":"crossref","unstructured":"Saratsis, A.M., Knowles, T., Petrovic, A., and Nazarian, J. (2024). H3K27M mutant glioma: Disease definition and biological underpinnings. https:\/\/doi.org\/10.1093\/neuonc\/noad164.","DOI":"10.1093\/neuonc\/noad164"},{"key":"10.1016\/j.xcrm.2025.102204_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00432-018-02836-5","article-title":"High frequency of H3 K27M mutations in adult midline gliomas","volume":"145","author":"Ebrahimi","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib3","doi-asserted-by":"crossref","unstructured":"Al Sharie, S., Abu Laban, D., and Al-Hussaini, M. (2023). Decoding Diffuse Midline Gliomas: A Comprehensive Review of Pathogenesis, Diagnosis and Treatment. https:\/\/doi.org\/10.3390\/cancers15194869.","DOI":"10.3390\/cancers15194869"},{"key":"10.1016\/j.xcrm.2025.102204_bib4","doi-asserted-by":"crossref","unstructured":"Cooney, T., Lane, A., Bartels, U., Bouffet, E., Goldman, S., Leary, S.E.S., Foreman, N.K., Packer, R.J., Broniscer, A., Minturn, J.E., et al. (2017). Contemporary survival endpoints: An international diffuse intrinsic pontine glioma registry study. https:\/\/doi.org\/10.1093\/neuonc\/nox107.","DOI":"10.1093\/neuonc\/nox107"},{"key":"10.1016\/j.xcrm.2025.102204_bib5","doi-asserted-by":"crossref","unstructured":"Van Den Bent, M., Saratsis, A.M., Geurts, M., and Franceschi, E. (2024). H3 K27M-Altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions. https:\/\/doi.org\/10.1093\/neuonc\/noad220.","DOI":"10.1093\/neuonc\/noad220"},{"key":"10.1016\/j.xcrm.2025.102204_bib6","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/eji.201970107","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)","volume":"49","author":"Cossarizza","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102204_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/neuonc\/noy145","article-title":"Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy","volume":"21","author":"Lieberman","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","article-title":"The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location","volume":"54","author":"Liu","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102204_bib9","doi-asserted-by":"crossref","unstructured":"Persson, M.L., Douglas, A.M., Alvaro, F., Faridi, P., Larsen, M.R., Alonso, M.M., Vitanza, N.A., and Dun, M.D. (2022). The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. https:\/\/doi.org\/10.1093\/neuonc\/noac117.","DOI":"10.1093\/neuonc\/noac117"},{"key":"10.1016\/j.xcrm.2025.102204_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-018-2991-5","article-title":"Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience","volume":"140","author":"Kline","year":"2018","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11060-020-03578-6","article-title":"Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: a single institution experience","volume":"149","author":"Cacciotti","year":"2020","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102204_bib13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102204_bib14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102204_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102204_bib16","first-page":"120","article-title":"A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency","volume":"7","author":"Suzuki","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102204_bib17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2025.102204_bib18","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102204_bib19","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Mart\u00ednez-V\u00e9lez","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102204_bib20","doi-asserted-by":"crossref","unstructured":"Yang, K., Halima, A., and Chan, T.A. (2023). Antigen presentation in cancer \u2014 mechanisms and clinical implications for immunotherapy. https:\/\/doi.org\/10.1038\/s41571-023-00789-4.","DOI":"10.1038\/s41571-023-00789-4"},{"key":"10.1016\/j.xcrm.2025.102204_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1158\/1078-0432.CCR-15-0234","article-title":"Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+T-cell-Mediated Tumor Control in the Genital Tract","volume":"22","author":"Sun","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102204_bib22","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102204_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2567.2010.03357.x","article-title":"Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages","volume":"132","author":"Buhtoiarov","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.xcrm.2025.102204_bib24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.celrep.2017.09.039","article-title":"Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution","volume":"21","author":"Mathys","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102204_bib25","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102204_bib26","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/neuonc\/now023","article-title":"Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models","volume":"18","author":"Shoji","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib27","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","article-title":"Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40","volume":"23","author":"Messenheimer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102204_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154812","article-title":"Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas","volume":"7","author":"Laspidea","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102204_bib29","article-title":"Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma","volume":"4","author":"Du Chatinier","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.xcrm.2025.102204_bib30","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102204_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2023.11.002","article-title":"A road map for the treatment of pediatric diffuse midline glioma","volume":"42","author":"Koschmann","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102204_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","article-title":"Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma","volume":"6","author":"Lin","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.xcrm.2025.102204_bib33","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/neuonc\/noz077","article-title":"Immunotherapy for pediatric brain tumors: past and present","volume":"21","author":"Foster","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102204_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12998-6","article-title":"Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies","volume":"10","author":"Medina-Echeverz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102204_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omto.2021.02.006","article-title":"Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform","volume":"20","author":"Yl\u00f6sm\u00e4ki","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2025.102204_bib38","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: Assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102204_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002644","article-title":"CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models","volume":"9","author":"Puigdelloses","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102204_bib40","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/neuonc\/noaa126","article-title":"Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors","volume":"22","author":"Wongthida","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118926","article-title":"A high-throughput in Vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent","volume":"10","author":"Halvorson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102204_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077639","article-title":"PD-0332991, a CDK4\/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma","volume":"8","author":"Barton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102204_bib43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","article-title":"Restricted replication of human adenovirus type 5 in mouse cell lines","volume":"14","author":"Blair","year":"1989","journal-title":"Virus Res."},{"key":"10.1016\/j.xcrm.2025.102204_bib44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1500078","article-title":"Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates","volume":"195","author":"Thompson","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102204_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Martinez-Velez","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.xcrm.2025.102204_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noae064.159","volume":"26","author":"Lindsay","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib47","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy","volume":"19","author":"Vonderheide","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102204_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000624","article-title":"CD40 agonist-induced IL-12p40 potentiates hepatotoxicity","volume":"8","author":"Bonnans","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102204_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.xcrm.2025.102204_bib50","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","article-title":"TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory","volume":"41","author":"Ausejo-Mauleon","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102204_bib51","article-title":"Therapeutic manipulation and bypass of the blood\u2013brain barrier: powerful tools in glioma treatment","volume":"7","author":"Giantini-Larsen","year":"2025","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.xcrm.2025.102204_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf039","article-title":"Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG)","author":"Souweidane","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102204_bib53","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102204_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34791-8","article-title":"Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity","volume":"13","author":"Svensson-Arvelund","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102204_bib55","doi-asserted-by":"crossref","unstructured":"Lin, D., Shen, Y., and Liang, T. (2023). Oncolytic virotherapy: basic principles, recent advances and future directions. https:\/\/doi.org\/10.1038\/s41392-023-01407-6.","DOI":"10.1038\/s41392-023-01407-6"},{"key":"10.1016\/j.xcrm.2025.102204_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03037-x","article-title":"Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8 + T cell responses","volume":"9","author":"Malo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102204_bib57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2326-6066.CIR-22-0098","article-title":"The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain","volume":"11","author":"Bowman-Kirigin","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102204_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07685-x","article-title":"CSF1R regulates the dendritic cell pool size in adult mice via embryo-derived tissue-resident macrophages","volume":"9","author":"Percin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102204_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1834","article-title":"The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers","volume":"16","author":"Voissi\u00e8re","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102204_bib60","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102204_bib61","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102204_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102803","article-title":"Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry","volume":"5","author":"Ausejo-Mauleon","year":"2024","journal-title":"STAR Protoc."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125002770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125002770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:18:58Z","timestamp":1778919538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125002770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2666379125002770"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102204","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102204"}}